First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
SAN JUAN, Puerto Rico -- The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) ...
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.